Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arvinas to $38 from $55 and keeps a Neutral rating on the shares. The analyst updated biotechnology models to reflect reported Q4 and 2023 financials.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas appoints Randy Teel Chief Business Officer
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
- Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
- Arvinas price target lowered to $87 from $90 at H.C. Wainwright
- Arvinas Partners with Novartis on Prostate Cancer Therapy
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue